No Clear Advantage of Ticagrelor vs. Clopidogrel in Complex PCI for Chronic Coronary Syndrome

15 Feb 2024 • In the ALPHEUS trial, evaluating chronic coronary syndrome patients undergoing complex PCI, the use of ticagrelor did not reduce the rate of periprocedural MI and major myocardial injuries compared to clopidogrel.

Despite complex PCI patients having elevated rates of periprocedural and cardiovascular events, ticagrelor did not outperform clopidogrel in mitigating these risks. Bleeding risks were low and similar in both groups.

There does not appear to be a benefit of stronger platelet suppression with ticagrelor compared to clopidogrel among patients with complex stable CAD.

Source: JACC | Read full story

Contact us

+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd